FTC Must Tackle Anti-Competitive Drug Rebate Practices
Law360 (May 17, 2019, 3:22 PM EDT) -- Pharmaceutical manufacturers have implemented a strategy to block and delay entry of new innovative drugs from the market through a contracting practice that creates what is known as a “rebate wall” or “rebate trap”. While rebates can be procompetitive if they lead to lower prices for consumers, some drug manufacturers are structuring rebates to limit competition from rivals in an effort to protect their monopolies.
This article sets forth how the Federal Trade Commission can examine and challenge rebate walls. First, this article provides a detailed explanation of rebate walls. Second, it outlines how they harm consumers. Third, it provides a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!